# A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

> **NCT05758610** · PHASE1 · RECRUITING · sponsor: **Shengke Pharmaceuticals (Jiangsu) Limited, China** · enrollment: 60 (estimated)

## Conditions studied

- NHL, Adult
- AML, Adult Recurrent

## Interventions

- **DRUG:** ETH-155008

## Key facts

- **NCT ID:** NCT05758610
- **Lead sponsor:** Shengke Pharmaceuticals (Jiangsu) Limited, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-04
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758610, "A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05758610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*